Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0987 |
Gimeracil
吉美嘧啶,吉莫斯特,Gimestat |
Autophagy | Autophagy |
Gimeracil (Gimestat) 是一种竞争性可逆的 DPYD(二氢嘧啶脱氢酶,DPD) 有效抑制剂,是口服氟嘧啶衍生物 S-1 的成分,能够抑制 DNA DSB 的修复。 | |||
T79799 |
pan-KRAS-IN-4
|
Ras | GPCR/G Protein; MAPK |
Pan-KRAS-IN-4 (compound 5) 为一种高效KRAS抑制剂,其IC50值分别为0.37 nM (Kras G12C) 和0.19 nM (Kras G12V)。 | |||
T6877 |
LJH685
|
Apoptosis; S6 Kinase | Apoptosis; MAPK; PI3K/Akt/mTOR signaling |
LJH685 是一种选择性,ATP-竞争性的RSK 抑制剂, 抑制 RSK1/2/3 生物活性,IC50为 6、5、4 nM。 | |||
T6878 |
LJI308
|
S6 Kinase | MAPK; PI3K/Akt/mTOR signaling |
LJI308 是泛RSK 抑制剂,对 RSK1、RSK2 和 RSK3 的IC50分别为 6、4 和 13 nM。它抑制辐照、EGF 处理和表达 KRAS 突变的细胞中 RSK (T359/S363) 和 YB-1 (S102) 的磷酸化。 | |||
T6719 |
Varlitinib
ASLAN001,ARRY-334543 |
HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Varlitinib (ASLAN001) 是有效,可逆的泛 EGFR 小分子抑制剂,对 HER1,HER2 和 HER4 的 IC50 值分别为7,2,4 nM。 | |||
T6836 |
FIIN-2
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FIIN2 是一种 FGFR 的不可逆抑制剂,能够抑制 FGFR1 (IC50:3.1 nM),FGFR2 (IC50:4.3 nM),FGFR3 (IC50:27 nM) 和 FGFR4 (IC50:45 nM)。 | |||
T7017 |
WNK463
|
Serine/threonin kinase | Cell Cycle/Checkpoint; Metabolism |
WNK463 是口服有活性的 WNK 激酶抑制剂,能够抑制 WNK1 (IC50:5 nM)、WNK2 (IC50:1 nM)、WNK3 (IC50:6 nM)及 WNK4 (IC50:9 nM)。 | |||
T77661 |
h-NTPDase-IN-4
|
Phosphatase | Metabolism |
h-NTPDase-IN-4 是 NTPDase 的泛抑制剂,对 h-NTPDase1, 1h-NTPDase2, h-NTPDase3, h-NTPDase8具有抑制作用,IC50 分别为 3.58 μM , 10.21 μM , 0.13 μM , 13.57 μM 。 | |||
T19649 |
PF-06273340
PF 6273340,PF 06273340,PF6273340,PF-6273340 |
Trk receptor | Tyrosine Kinase/Adaptors |
PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。 | |||
T6380 |
AMG 900
AMG900,AMG-900,莪术醇.姜黄醇 |
p38 MAPK; Tyrosine Kinases; Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic; MAPK; Tyrosine Kinase/Adaptors |
AMG 900 是一种有效且高度选择性的泛极光激酶抑制剂,对Aurora A、B 和C 的IC50分别为 5 nM、4 nM 和 1 nM。 | |||
T14214 |
AMG 511
|
PI3K | PI3K/Akt/mTOR signaling |
AMG 511 是一种高效的、口服有效的 I 类 pan-PI3K 抑制剂,对 PI3Kα, β, δ 和 γ 作用的 Ki 值分别为 4 nM, 6 nM, 2 nM 和 1 nM。它它显著抑制了 PI3K 信号,减少 p-Akt (Ser473)。它在小鼠胶质母细胞瘤移植瘤模型中具有抗肿瘤作用。 | |||
T13058 |
T025
|
CDK | Cell Cycle/Checkpoint |
T025 是一种泛 CLK 抑制剂,对 CLK1-4 的 Kd 分别为 4.8、0.096、6.5、0.61 和 0.074 nM。 T025 在血液学和实体癌细胞系中表现出抗增殖活性,IC50 为 30-300 nM。 T025 可用于 MYC 驱动疾病的研究。 | |||
T2235 |
Dactolisib
2-甲基-2-[4-[3-甲基-2-氧代-8-(喹啉-3-基)-2,3-二氢咪唑并[4,5-c]喹啉-1-基]苯基]丙腈,BEZ235,NVP-BEZ235 |
ATM/ATR; PI3K; mTOR; Autophagy | Autophagy; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
Dactolisib (BEZ235) 是一种可口服的 pan-class IPI3K 和 mTOR 抑制剂,抑制 mTORC1和 mTORC2,作用于 p110α/γ/δ/β和 mTOR,IC50分别为 4 nM/5 nM/7 nM/75 nM 和 20.7 nM。 | |||
T3334 |
Velpatasvir
GS-5816,维帕他韦 |
HCV Protease; SARS-CoV | Microbiology/Virology; Proteases/Proteasome |
Velpatasvir (GS-5816) 是一种的 HCV NS5A 抑制剂。它也是 SARS-CoV 3CLpro 的抑制剂,IC50为 2.16 μM。 | |||
T6055 |
Quisinostat
奎诺司他,JNJ-26481585 |
Apoptosis; HDAC; Autophagy | Apoptosis; Autophagy; Chromatin/Epigenetic; DNA Damage/DNA Repair |
Quisinostat (JNJ-26481585) 是一种高效的,具有口服活性的 pan-HDAC 抑制剂,对 HDAC1、HDAC2、HDAC4、HDAC10、HDAC11 作用的 IC50值范围为 0.11-0.64 nM。它在成神经细胞瘤中能诱导自噬,具有广泛的抗肿瘤活性。 | |||
T6865 |
Quisinostat dihydrochloride
Quisinostat 2HCl,Quisinostat (JNJ-26481585) 2HCl,JNJ26854165(Quisinostat) 2HCl,JNJ-26481585 2HCl |
Apoptosis; HDAC; Autophagy | Apoptosis; Autophagy; Chromatin/Epigenetic; DNA Damage/DNA Repair |
Quisinostat dihydrochloride (JNJ26854165(Quisinostat) 2HCl) 是一种有口服活性,高效的 pan-HDAC 抑制剂,具有广泛的抗肿瘤活性。它对 HDAC1、HDAC2、HDAC4、HDAC10和HDAC11 的IC50值分别为 0.11 nM、0.33 nM、0.64 nM、0.46 nM 和 0.37 nM。 | |||
T17169 |
Trk-IN-4
PF-6683324 isomer |
Trk receptor | Tyrosine Kinase/Adaptors |
Trk-IN-4 is an effective pan-Trk inhibitor in cell-based assays (IC50s: 1.9 nM, 2.6 nM, and 1.1 nM for TrkA, TrkB, and TrkC, respectively). | |||
T37085 |
Luxeptinib
|
||
Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4]. | |||
T74495 | NS5A-IN-4 | ||
NS5A-IN-4 (Compound 1.12) 是一种具有口服活性的泛基因型丙型肝炎病毒 (HCV)NS5A 抑制剂,对gT1b、gT1a、gT2a、gT3a,gT4a 和gT5a 的IC50分别为 1.2、2296、4.6、362、10.3 和 693 pM。 | |||
T63770 |
PI3K/mTOR Inhibitor-4
|
||
PI3K/mTOR Inhibitor-4 是一种口服具有活力的泛 I 类 PI3K/mTOR 抑制剂。PI3K/mTOR Inhibitor-4 具有酶抑制作用,能够作用于 PI3Kα (IC50: 0.63 nM)、PI3Kγ (IC50: 22 nM)、PI3Kδ (IC50: 9.2 nM) 和 mTOR (IC50: 13.85 nM)。PI3K/mTOR Inhibitor-4 能够用于研究癌症。 | |||
T68039 | cep-5214 | ||
CEP-5214是一种有效的、低纳摩尔的人 VEGF-R 酪氨酸激酶泛抑制剂,对 VEGF-R1/FLT-1、VEGF-R2/KDR 和VEGF-R3/FLT-4的IC50分别为16、8和4 nM,细胞活性与分离的酶活性相当。 | |||
T38847 |
Vevorisertib
Vevorisertib,ARQ 751 |
||
Vevorisertib (ARQ 751) is a highly effective oral compound that selectively inhibits pan-AKT serine/threonine kinases such as AKT1 (with an IC50 value of 0.55 nM), AKT2 (with an IC50 value of 0.81 nM), and AKT3 (with an IC50 value of 1.31 nM). This compound, either as a standalone treatment option or in combination with other anti-cancer agents, is ideally suited for conducting research on solid tumors characterized by PIK3CA/AKT/PTEN mutations[4]. | |||
T69200 | CGP74514A | ||
CGP74514A is a CDK1 inhibitor with potential anticancer activity. In U937 cells, CGP74514A - induced apoptosis (5 microM) became apparent within 4 hr and approached 100% by 24 hr. The pan- caspase inhibitor Boc-fmk and the caspase-8 inhibitor lETD-fmk opposed CGP74514A -induced caspase-9 activation and PARP degradation, but not cytochrome c or Smac/DIABLO release. CGP74514A -mediated apoptosis was substantially blocked by ectopic expression of full-length Bel- 2, a loop-deleted mutant Bcl-2, and... | |||
T35771 | Destruxin B2 | ||
Destruxin B2 is a cyclic hexadepsipeptide mycotoxin that has been found in M. anisopliae and has antiviral, insecticidal, and phytotoxic activities.1,2,3 It inhibits secretion of hepatitis B virus surface antigen (HBsAg) by Hep3B cells expressing hepatitis B virus (HBV) DNA (IC50 = 1.3 μM).1 Destruxin B2 is toxic to Sf9 insect cells in an electric cell-substrate impedance sensing (ECIS) test with a 50% inhibitory concentration (ECIS50) value of 92 μM.4 It is also phytotoxic to B. napus leaves.3 ... | |||
T38381 |
CAY17c
|
||
CAY17c is an inhibitor of bromodomain-containing protein 4 (BRD4; IC50= 0.71 μM), as well as class I histone deacetylases (HDACs; IC50s = 0.046, 0.058, 0.075, and 0.167 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 0.073 and 0.923 μM for HDAC6 and HDAC10, respectively).1It is selective for these enzymes over BRD2, -3, and -T (IC50s = >20 μM for all), as well as over HDAC4, -5, -7, -9, and -11 (IC50s = >10 μM for all). CAY17c inhibits the proliferation of HCT116, SW620,... | |||
T36996 |
MSA-2 dimer
|
||
MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (Kd=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide[1]. MSA-2 dimer (60 mg/kg; p.o.; 50 days) inhibits tumor growth and prolongs overall survival[1]. MSA-2 dimer (40 mg/kg; s.c.; 25 days) induces complete tumor regression[1].MSA-2 dimer (60 mg/kg; p.o.; 4 hours) increases proinflammatory cytokine (IFN-β) le... |